BioSpace News Archive

Polygon Global Partners LLP acts as investment manager to funds and accounts that hold a total of 859,610 ordinary shares and 1,750,000 preferred shares of Biotest AG, representing approximately 6.59% of the share capital of the company. Yesterday, funds and accounts managed by Polygon filed an application with the competent court for autho

ReWalk Robotics Ltd. announced that it has entered into definitive agreements with several institutional investors providing for the issuance of approximately 4,938,278 of the Company’s ordinary shares, at a purchase price of $1.8225, in a registered direct offering priced at-the-market under Nasdaq Rules.

BiondVax Pharmaceuticals Ltd. announced that all participants in the placebo-controlled, blinded, pivotal, clinical efficacy, Phase 3 trial of BiondVax’s M–001 universal influenza vaccine candidate have now completed their site visits.

New York Cancer & Blood Specialists, one of the leading oncology practices in the nation, announced it has partnered with The Brooklyn Hospital Center, an independent community hospital, to build a new comprehensive cancer care facility, The Brooklyn Cancer Center.

Engage Surgical, a privately held orthopedic implant company, announces FDA 510 clearance of the only cementless partial knee system available in the USA.

July 1, 2020 10:00 UTC IRVING, Texas--( BUSINESS WIRE )-- A study facilitated by Vizient, Inc. and recently published in the Journal of American Medical Association Internal Medicine yielded new insights about patients with presumed penicillin allergies. The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies. Because 90% of documented penicill

Niclosamide has been identified as a potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea, with potency >40x higher than remdesivir

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that the Investigational New Drug Application for MN-166 for prevention of Acute Respiratory Distress Syndrome has been accepted and is now open with the U.S. Food and Drug Administration.

Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development

Golden Biotechnology Corp., a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug application for a Phase II clinical trial of Antroquinonol on COVID-19 patients in USA.